RAPT Therapeutics, Inc. (RAPT) Income from Continuing Operations (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Income from Continuing Operations for 5 consecutive years, with 54465000.0 as the latest value for Q4 2024.
- Quarterly Income from Continuing Operations fell 63.97% to 54465000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 136101000.0 through Dec 2024, down 7.11% year-over-year, with the annual reading at 136101000.0 for FY2024, 7.11% down from the prior year.
- Income from Continuing Operations hit 54465000.0 in Q4 2024 for RAPT Therapeutics, down from 19788000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 12387000.0 in Q2 2020 to a low of 54465000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 23415700.0 across 5 years, with a median of 20282500.0 in 2022.
- Biggest YoY gain for Income from Continuing Operations was 41.66% in 2024; the steepest drop was 63.97% in 2024.
- Year by year, Income from Continuing Operations stood at 12735000.0 in 2020, then fell by 19.27% to 15189000.0 in 2021, then tumbled by 60.85% to 24431000.0 in 2022, then plummeted by 35.96% to 33217000.0 in 2023, then plummeted by 63.97% to 54465000.0 in 2024.
- Business Quant data shows Income from Continuing Operations for RAPT at 54465000.0 in Q4 2024, 19788000.0 in Q3 2024, and 29330000.0 in Q2 2024.